Immune Tolerance in Allergy & Asthma

Allergen immunotherapy, which helps reduce sensitization by giving gradually increasing doses of an allergen, can improve symptoms for many people but the effects are often not permanent. The Immune Tolerance Network (ITN) is focused on achieving long-lasting tolerance to allergens by investigating treatment approaches that improve on current immunotherapy methods, such as combining immunotherapy with other agents to enhance responses, or exploring new allergen preparations and routes of administration to maximize effectiveness.

This page contains a list of ITN's allergy and asthma clinical trials that are currently enrolling participants. To see all of ITN's active and completed studies in allergy and asthma, please visit For Researchers.

Javascript is required to view this map.

Clinical Trials - Allergy & Asthma

Anti-TSLP Plus Antigen-Specific Immunotherapy For Induction Of Tolerance In Individuals With Cat Allergy (CATNIP)

Principal Investigator:
Jonathan Corren, MD, University of California, Los Angeles, Los Angeles, CA

CATNIP is a clinical research trial, which will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP antibody being co-developed by Amgen and Medimmune) can lead to lasting tolerance to cat allergen. This study will implement the concept referred to as “allergen-plus,” which aims to enhance the disease-modifying mechanisms of allergen-specific immunotherapy by combining it with other anti-inflammatory or immune-modulating agents.

Learn more: